Homocystinuria: Treatment With N-Acetylcysteine (NCT00483314) | Clinical Trial Compass
CompletedPhase 2
Homocystinuria: Treatment With N-Acetylcysteine
Canada5 participantsStarted 2007-11
Plain-language summary
The purpose of this study is determine if oral N-acetylcysteine is effective in lowering homocysteine in individuals with homocystinuria.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Homocystinuria (lens dislocation and hyperhomocysteinemia)
* Age ≥ 18 (the age of majority in Canada)
Exclusion Criteria:
* Nursing mothers or pregnant women
* Chronic liver disease
* Taking nitrates
* Cystine stone formers
* History of active peptic ulcer disease
* Subjects receiving carbamazepine and metoclopramide
* Use of other products containing cysteine or N-acetylcysteine (e.g. nebulized NAC, cysteine supplements, methionine restriction)
* Hypersensitivity to any ingredient in the study product
* Clinically significant, abnormal laboratory test on screening (Visit 2)
Other Criteria:
* Women of child-bearing capacity must be using an acceptable method of birth control and have a negative pregnancy test before being enrolled
What they're measuring
1
Lowering plasma total homocysteine
Timeframe: 3 months
Trial details
NCT IDNCT00483314
SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre